Navigation Links
Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Date:2/17/2009

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that GlaxoSmithKline (NYSE: GSK) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria(R) (albiglutide) in the long-term treatment of type 2 diabetes mellitus. As a result, HGS will receive a $9 million milestone payment in the first quarter of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We are delighted that GSK has advanced Syncria to Phase 3 development, and we look forward to the future progress of this important program," said H. Thomas Watkins, President and Chief Executive Officer, HGS.

Syncria is the fifth product to which HGS has substantial financial rights that has entered late-stage clinical development. It is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $24 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.

Attached is a press release issued earlier this morning by GSK (http://tinyurl.com/crprkt) announcing initiation of the Phase 3 program for Syncria. All inquiries regarding the dev
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
2. 14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging
3. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
4. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
5. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
6. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
7. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
8. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
9. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... Miami, FL (PRWEB) May 21, 2013 ... and breakouts as contributor to acne. Recently physicians from ... effects of mental stress on the skin, and suggested ... to help reduce the chemicals produced from stress that ... aside from the negative feelings acne brings about, stress ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... ... to obtain relevant information and accuracy beyond Search Engine Optimization , ... Malaga, Spain (Vocus) August 26, 2009 ... solutions, will present on September 1st at the Association for Medical Education ...
... , WELLESLEY HILLS, Mass., Aug. 25 Joseph F. ... Phase 2b/3 will be part of the intellectual property offered for sale ... , , The PRX-00023 is ... molecule, oral 5HT1A Agonist for CNS disorders. It is well tolerated ...
... JERUSALEM, August 25 Oramed Pharmaceuticals,Inc. (OTCBB: ... today announced that it is the recipient of the ... Award. , Oramed Pharmaceuticals is ... drugs and vaccines delivered via injection. Oramed,focuses on the ...
Cached Biology Technology:iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference 2EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction 2Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award 2Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award 3
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... available in pharmacies and health stores, phosphatidylserine is ... and soy. Proven to improve cognition and slow ... people experiencing memory impairment. Now a team headed ... of Tel Aviv University,s Department of Human ... supplement improves the functioning of genes involved in ...
(Date:5/21/2013)... Try staying fit in space, where living quarters are ... That,s the challenge a group of Michigan State University ... grant from NASA. Their goal is to keep astronauts ... could give astronauts the best exercise regimen there is, ... it, it isn,t going to help," said project leader ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
... Geology and Geophysics at Yale and his colleagues mapped ... 45 - 25 million years ago based on stable ... reported in Science Express. , "Through the energy we ... greenhouse gasses, such as carbon dioxide and methane, in ...
... Geology and Geophysics at Yale and his colleagues mapped ... 45 - 25 million years ago based on stable ... reported in Science Express. , "Through the energy we ... greenhouse gasses, such as carbon dioxide and methane, in ...
... in the Department of Geology and Geophysics at Yale ... atmospheric carbon dioxide between 45 - 25 million years ... National Science Foundation study reported in Science Express. , ... a contribution to increasing greenhouse gasses, such as carbon ...
Cached Biology News:Stem cells grown in lab mirror normal developmental steps 2Invasive parasite destroying fish species 2Deep sea algae connect ancient climate, carbon dioxide and vegetation 2
...
... Lyophilized solid. Supplied as a trifluoroacetate ... INERT GAS. A cell-permeable mutated analog of ... that serves as a negative control. Does ... Purity: ≥97% by HPLC. Soluble in ...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... The powerful solution for all plate washing ... format. ,The PW 384 provides an ... field of Drug Discovery (Assay development, Screening or ... speed ,The PW 384 has set ...
Biology Products: